US5959096A
(en)
*
|
1992-03-16 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
US20060270624A1
(en)
*
|
1991-12-24 |
2006-11-30 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US6277603B1
(en)
|
1991-12-24 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
EP0618925B2
(de)
*
|
1991-12-24 |
2012-04-18 |
Isis Pharmaceuticals, Inc. |
Antisense oligonukleotide
|
US5700922A
(en)
*
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
US5922686A
(en)
*
|
1992-03-16 |
1999-07-13 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of protein kinase C
|
US5882927A
(en)
*
|
1992-03-16 |
1999-03-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of protein kinase C
|
US5681747A
(en)
*
|
1992-03-16 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
|
US5948898A
(en)
*
|
1992-03-16 |
1999-09-07 |
Isis Pharmaceuticals, Inc. |
Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
|
US5916807A
(en)
*
|
1992-03-16 |
1999-06-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US5885970A
(en)
*
|
1992-03-16 |
1999-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US6153599A
(en)
*
|
1992-03-16 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
|
US6117847A
(en)
*
|
1992-03-16 |
2000-09-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for enhanced modulation of protein kinase C expression
|
TW244371B
(de)
*
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
JP2739769B2
(ja)
*
|
1992-10-05 |
1998-04-15 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ras遺伝子のアンチセンスオリゴヌクレオチドによる阻害
|
DE59407895D1
(de)
*
|
1993-05-12 |
1999-04-15 |
Novartis Ag |
Nukleoside und Oligonukleotide mit 2'-Ethergruppen
|
US6294664B1
(en)
|
1993-07-29 |
2001-09-25 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides
|
IL111660A
(en)
*
|
1993-11-16 |
2005-05-17 |
Genta Inc |
Oligonucleoside compounds for effecting rnaseh-mediated cleavage of a target ribonucleic acid sequence and a pharmaceutical composition containing them
|
US6410518B1
(en)
*
|
1994-05-31 |
2002-06-25 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
US6624293B1
(en)
|
1995-08-17 |
2003-09-23 |
Hybridon, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
US7074768B2
(en)
|
1995-08-17 |
2006-07-11 |
Idera Pharmaceuticals, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
US5652356A
(en)
*
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
US5856099A
(en)
*
|
1996-05-21 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Antisense compositions and methods for modulating type I interleukin-1 receptor expression
|
AU3029797A
(en)
|
1996-06-06 |
1998-01-05 |
Novartis Ag |
2'-substituted nucleosides and oligonucleotide derivatives
|
US7070925B1
(en)
|
1996-07-16 |
2006-07-04 |
Gen-Probe Incorporated |
Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
|
CA2260749A1
(en)
*
|
1996-07-16 |
1998-01-22 |
Gen-Probe Incorporated |
Methods for detecting rna analytes using modified probes
|
US6025133A
(en)
*
|
1996-12-30 |
2000-02-15 |
Gen-Probe Incorporated |
Promoter-sequestered oligonucleoside and method of use
|
CA2286304C
(en)
|
1997-04-10 |
2007-08-07 |
Diagnocure Inc. |
Pca3, pca3 genes, and methods of use
|
DE19741739B4
(de)
*
|
1997-09-22 |
2006-04-27 |
Nanogen Recognomics Gmbh |
Supramolekulares Paarungssystem, dessen Herstellung und Verwendung
|
US6007992A
(en)
*
|
1997-11-10 |
1999-12-28 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US6028183A
(en)
|
1997-11-07 |
2000-02-22 |
Gilead Sciences, Inc. |
Pyrimidine derivatives and oligonucleotides containing same
|
US6007995A
(en)
*
|
1998-06-26 |
1999-12-28 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of TNFR1 expression
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
US6673912B1
(en)
|
1998-08-07 |
2004-01-06 |
Isis Pharmaceuticals, Inc. |
2′-O-aminoethyloxyethyl-modified oligonucleotides
|
DE60041489D1
(de)
*
|
1999-07-09 |
2009-03-19 |
Gen Probe Inc |
Nachweis von hiv-1 durch amplifizierung von nukleinsäuren
|
ES2260059T3
(es)
|
1999-09-29 |
2006-11-01 |
Diagnocure Inc. |
Rna mensajero del pca3 en tejidos benignos y malignos de prostata.
|
DE60040874D1
(de)
|
2000-09-01 |
2009-01-02 |
Gen Probe Inc |
Amplifizierung von hiv-1 sequenzen zur detektion ven einhergehen
|
US6582920B2
(en)
|
2000-09-01 |
2003-06-24 |
Gen-Probe Incorporated |
Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
|
CN1471537A
(zh)
*
|
2000-09-07 |
2004-01-28 |
ƽ |
用于低聚核苷酸合成的合成子
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
DE10159904A1
(de)
*
|
2001-12-06 |
2003-07-03 |
Adnagen Ag |
Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür
|
US20090137513A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20090306182A1
(en)
*
|
2002-02-20 |
2009-12-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MAP KINASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20090137507A1
(en)
*
|
2002-02-20 |
2009-05-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF ANGIOPOIETIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP1432724A4
(de)
*
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
|
US20090093439A1
(en)
*
|
2002-02-20 |
2009-04-09 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US7163927B2
(en)
*
|
2002-05-23 |
2007-01-16 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
WO2003106714A1
(en)
|
2002-06-14 |
2003-12-24 |
Gen-Probe Incorporated |
Compositions and methods for detecting hepatitis b virus
|
PT1527176E
(pt)
|
2002-08-05 |
2007-04-30 |
Atugen Ag |
Novas formas de muléculas de arn de interferência
|
ES2890882T3
(es)
|
2002-10-16 |
2022-01-24 |
Gen Probe Inc |
Composiciones y procedimientos para detectar el virus del Nilo occidental
|
EP2141233B1
(de)
|
2002-11-18 |
2016-10-19 |
Roche Innovation Center Copenhagen A/S |
Antisense-Entwurf
|
WO2004070056A2
(en)
|
2003-02-07 |
2004-08-19 |
Diagnocure Inc. |
Method to detect prostate cancer in a sample
|
WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
ATE549421T1
(de)
|
2003-12-19 |
2012-03-15 |
Gen Probe Inc |
Zusammensetzungen, verfahren und kits zum nachweis der nukleinsäuren von hiv-1 und hiv-2
|
NZ597400A
(en)
|
2004-02-18 |
2013-06-28 |
Chromocell Corp |
Methods and Materials Using Signaling Probes
|
EP2700720A3
(de)
*
|
2004-03-15 |
2015-01-28 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
EA012799B1
(ru)
|
2004-08-16 |
2009-12-30 |
Кварк Фармасьютикалс, Инк. |
Терапевтические применения ингибиторов rtp801
|
AU2005291899A1
(en)
|
2004-09-30 |
2006-04-13 |
Gen-Probe Incorporated |
Assay for detecting and quantifying HIV-1
|
US20060223080A1
(en)
|
2004-11-09 |
2006-10-05 |
Gen-Probe Incorporated |
Compositions and methods for detecting group a streptococci
|
US20060166234A1
(en)
|
2004-11-22 |
2006-07-27 |
Barbara Robertson |
Apparatus and system having dry control gene silencing compositions
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
CA2491067A1
(en)
|
2004-12-24 |
2006-06-24 |
Stichting Katholieke Universiteit |
Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
|
JP4874999B2
(ja)
|
2005-02-07 |
2012-02-15 |
ジェン−プローブ・インコーポレーテッド |
B群連鎖球菌属を検出するための組成物及び方法
|
CA2605015C
(en)
|
2005-05-06 |
2013-09-10 |
Gen-Probe Incorporated |
Compositions and assays to detect influenza virus a and b nucleic acids
|
EP1937847A2
(de)
|
2005-10-17 |
2008-07-02 |
Gen-Probe Incorporated |
Zusammensetzungen und verfahren zum nachweis von legionella pneumophila-nukleinsäure
|
US8258109B2
(en)
*
|
2005-10-20 |
2012-09-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of LMNA expression
|
NL2000439C2
(nl)
|
2006-01-20 |
2009-03-16 |
Quark Biotech |
Therapeutische toepassingen van inhibitoren van RTP801.
|
EP2397148A3
(de)
|
2006-02-02 |
2012-04-25 |
Allergan, Inc. |
Zusammensetzungen und Verfahren zur Behandlung von Augenerkrankungen
|
EP2021513B1
(de)
|
2006-05-12 |
2011-06-29 |
Gen-Probe Incorporated |
Zusammensetzungen und verfahren für den nachweis von enterokokken-nukleinsäuren
|
CN101490253A
(zh)
|
2006-07-21 |
2009-07-22 |
赛伦斯治疗公司 |
用于抑制蛋白激酶3表达的方法
|
AU2007281143B2
(en)
|
2006-08-01 |
2011-05-19 |
Gen-Probe Incorporated |
Methods of nonspecific target capture of nucleic acids
|
AU2007299705B2
(en)
|
2006-09-22 |
2012-09-06 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のsiRNAおよびその使用方法
|
WO2008052774A2
(en)
|
2006-10-31 |
2008-05-08 |
Noxxon Pharma Ag |
Methods for detection of a single- or double-stranded nucleic acid molecule
|
US9938641B2
(en)
|
2006-12-18 |
2018-04-10 |
Fluidigm Corporation |
Selection of aptamers based on geometry
|
JP5340167B2
(ja)
|
2006-12-21 |
2013-11-13 |
ジェン−プロウブ インコーポレイテッド |
核酸増幅のための方法および組成物
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
WO2009108217A2
(en)
*
|
2007-09-18 |
2009-09-03 |
Intradigm Corporation |
Compositions comprising k-ras sirna and methods of use
|
US20100280097A1
(en)
*
|
2007-09-18 |
2010-11-04 |
Intradigm Corporation |
Compositions comprising hif-1 alpha sirna and methods of use thereof
|
CA2701845A1
(en)
|
2007-10-03 |
2009-04-09 |
Quark Pharmaceuticals, Inc. |
Novel sirna structures
|
EP2214700A4
(de)
*
|
2007-11-02 |
2012-08-22 |
Janssen Biotech Inc |
Halbsynthetische glp-1-peptid-fusionskonstrukte, verfahren und verwendungen
|
CA2715991A1
(en)
|
2007-12-26 |
2009-07-09 |
Gen-Probe Incorporated |
Amplification oligomers and methods to detect candida albicans 26s rrna or encoding dna
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
WO2009114726A1
(en)
*
|
2008-03-12 |
2009-09-17 |
Intradigm Corporation |
Compositions comprising notch1 sirna and methods of use thereof
|
CA2721536A1
(en)
|
2008-04-21 |
2009-10-29 |
Gen-Probe Incorporated |
Method for detecting chikungunya virus
|
US8097412B2
(en)
|
2008-07-12 |
2012-01-17 |
Biodiagnostics, Inc. |
DNA-based test for detection of annual and intermediate ryegrass
|
MX2011000603A
(es)
|
2008-07-18 |
2011-03-02 |
Oncogenex Technologies Inc |
Formulacion antisentido.
|
JP5645840B2
(ja)
|
2008-12-02 |
2014-12-24 |
株式会社Wave Life Sciences Japan |
リン原子修飾核酸の合成方法
|
US20110288155A1
(en)
|
2008-12-18 |
2011-11-24 |
Elena Feinstein |
Sirna compounds and methods of use thereof
|
WO2010091878A2
(en)
|
2009-02-13 |
2010-08-19 |
Silence Therapeutics Ag |
Means for inhibiting the expression of opa1
|
US8829179B2
(en)
|
2009-02-18 |
2014-09-09 |
Silence Therapeutics Gmbh |
Means for inhibiting the expression of ANG2
|
CA2756659A1
(en)
|
2009-02-26 |
2010-09-02 |
Gen-Probe Incorporated |
Assay for detection of human parvovirus nucleic acid
|
US9169512B2
(en)
|
2009-07-01 |
2015-10-27 |
Gen-Probe Incorporated |
Methods and compositions for nucleic acid amplification
|
CN102596204B
(zh)
|
2009-07-06 |
2016-11-23 |
波涛生命科学有限公司 |
新的核酸前药及其使用方法
|
US8236570B2
(en)
|
2009-11-03 |
2012-08-07 |
Infoscitex |
Methods for identifying nucleic acid ligands
|
US8841429B2
(en)
|
2009-11-03 |
2014-09-23 |
Vivonics, Inc. |
Nucleic acid ligands against infectious prions
|
US9733242B2
(en)
|
2012-10-07 |
2017-08-15 |
Sevident, Inc. |
Devices for capturing analyte
|
US9910040B2
(en)
|
2012-07-09 |
2018-03-06 |
Sevident, Inc. |
Molecular nets comprising capture agents and linking agents
|
DK2504435T3
(da)
|
2009-11-26 |
2019-12-09 |
Quark Pharmaceuticals Inc |
Sirna-forbindelser omfattende terminale substitutioner
|
WO2011072091A1
(en)
|
2009-12-09 |
2011-06-16 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the cns
|
TWI543763B
(zh)
|
2009-12-09 |
2016-08-01 |
日東電工股份有限公司 |
Hsp47表現之調節
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
EP3604558B1
(de)
|
2010-02-17 |
2022-10-12 |
Gen-Probe Incorporated |
Zusammensetzungen und verfahren zum nachweis von atopobium-vaginae-nukleinsäure
|
US9506057B2
(en)
|
2010-03-26 |
2016-11-29 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
EP3587593B1
(de)
|
2010-04-21 |
2023-09-27 |
Gen-Probe Incorporated |
Zusammensetzungen, verfahren und kits für den nachweis von nukleinsäuren des herpes-simplex-virus
|
AU2011261434B2
(en)
|
2010-06-02 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
AU2011270896B9
(en)
|
2010-06-24 |
2015-05-07 |
Quark Pharmaceuticals, Inc. |
Double stranded RNA compounds to RhoA and use thereof
|
EP2588629B1
(de)
|
2010-06-30 |
2017-05-17 |
Gen-Probe Incorporated |
Methode und apparatur zur identifizierung von analyt-beinhaltenden proben unter verwendung von single-read determination des analyten und prozesskontrollsignalen
|
EP3674423A1
(de)
|
2010-07-12 |
2020-07-01 |
Gen-Probe Incorporated |
Zusammensetzungen und assays zur erkennung von saisonaler h3-influenza a-virus-nukleinsäure
|
AU2011287430A1
(en)
|
2010-08-04 |
2013-03-21 |
Cizzle Biotechnology Limited |
Methods and compounds for the diagnosis and treatment of cancer
|
EP2611932A2
(de)
|
2010-08-30 |
2013-07-10 |
Gen-Probe Incorporated |
Zusammensetzungen, verfahren und reaktionsmischungen für den nachweis von xenotropic murine leukemia virus-related virus (xmrv)
|
AU2011299233B2
(en)
|
2010-09-07 |
2016-09-15 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
US9938590B2
(en)
|
2010-09-16 |
2018-04-10 |
Gen-Probe Incorporated |
Capture probes immobilizable via L-nucleotide tail
|
EP2620428B1
(de)
|
2010-09-24 |
2019-05-22 |
Wave Life Sciences Ltd. |
Asymmetrische hilfsgruppe
|
WO2012046219A2
(en)
|
2010-10-04 |
2012-04-12 |
Gen-Probe Prodesse, Inc. |
Compositions, methods and kits to detect adenovirus nucleic acids
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
EP3388532B1
(de)
|
2010-11-01 |
2021-03-10 |
Gen-Probe Incorporated |
Integrierte erfassung und amplifizierung von zielnukleinsäuren zur sequenzierung
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
WO2012065143A1
(en)
|
2010-11-12 |
2012-05-18 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
US8569220B2
(en)
|
2010-11-12 |
2013-10-29 |
Jelmar, Llc |
Hard surface cleaning composition
|
CN103298939A
(zh)
|
2010-12-06 |
2013-09-11 |
夸克医药公司 |
包含位置修饰的双链寡核苷酸化合物
|
EP2648763A4
(de)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
CA2828544A1
(en)
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
JP6000287B2
(ja)
|
2011-03-03 |
2016-09-28 |
クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. |
肺疾患および損傷を治療するための組成物および方法
|
USRE48732E1
(en)
|
2011-03-10 |
2021-09-14 |
Gen-Probe Incorporated |
Methods and compositions for the selection and optimization of oligonucleotide tag sequences
|
SG193923A1
(en)
|
2011-03-29 |
2013-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
JP2014511694A
(ja)
|
2011-04-03 |
2014-05-19 |
ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル |
修飾型rna(mod−rna)を使用する効率的なインビボタンパク質発現
|
EP3604559A1
(de)
|
2011-04-25 |
2020-02-05 |
Gen-Probe Incorporated |
Zusammensetzungen und verfahren zum nachweis von bv-assoziierter bakterieller nukleinsäure
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
MX360782B
(es)
|
2011-06-21 |
2018-11-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso.
|
EP3366312A1
(de)
|
2011-06-23 |
2018-08-29 |
Alnylam Pharmaceuticals, Inc. |
Serpina 1 sirnas: materialzusammensetzungen und verfahren zur behandlung
|
US9752201B2
(en)
|
2011-07-15 |
2017-09-05 |
Gen-Probe Incorporated |
Compositions and method for detecting human parvovirus nucleic acid and for detecting hepatitis A virus nucleic acids in single-plex or multiplex assays
|
JP6128529B2
(ja)
|
2011-07-19 |
2017-05-17 |
ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. |
官能化核酸の合成のための方法
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
EP3225698B1
(de)
|
2011-09-06 |
2019-07-31 |
Gen-Probe Incorporated |
Geschlossene nukleinsäurestrukturen
|
AU2012304520B2
(en)
|
2011-09-06 |
2016-06-16 |
Gen-Probe Incorporated |
Circularized templates for sequencing
|
AU2012304327B2
(en)
|
2011-09-08 |
2015-07-09 |
Gen-Probe Incorporated |
Compositions and methods for detecting BV-associated bacterial nucleic acid
|
US9580708B2
(en)
|
2011-09-14 |
2017-02-28 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotides compounds
|
MX356814B
(es)
|
2011-11-03 |
2018-06-13 |
Quark Pharmaceuticals Inc |
Métodos y composiciones para neuroprotección.
|
EP3848474A1
(de)
|
2011-11-04 |
2021-07-14 |
Gen-Probe Incorporated |
Molekulartestreagenzien und -verfahren
|
EP2776565A1
(de)
|
2011-11-08 |
2014-09-17 |
Quark Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen und zur behandlung von erkrankungen, störungen oder läsionen des nervensystems
|
DE102011120550B4
(de)
|
2011-12-05 |
2013-11-07 |
Gen-Probe Prodesse, Inc. |
Zusammensetzungen, Verfahren und Kits zur Detektion von Adenovirusnukleinsäuren
|
SG11201403756PA
(en)
|
2012-01-01 |
2014-11-27 |
Qbi Entpr Ltd |
Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
|
KR20140111673A
(ko)
|
2012-01-12 |
2014-09-19 |
쿠아크 파마수티칼스 인코퍼레이티드 |
청력 및 균형 장애를 치료하기 위한 조합요법
|
CN104169438B
(zh)
|
2012-02-01 |
2019-02-26 |
简·探针公司 |
非对称发夹靶标捕获低聚物
|
WO2013123996A1
(en)
|
2012-02-24 |
2013-08-29 |
Astrazeneca Uk Limited |
Novel sirna inhibitors of human icam-1
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
AU2013205110B2
(en)
|
2012-04-24 |
2016-10-13 |
Gen-Probe Incorporated |
Compositions, Methods and Kits to Detect Herpes Simplex Virus Nucleic Acids
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
AP2014008100A0
(en)
|
2012-05-16 |
2014-12-31 |
Gen Hospital Corp |
Compositions and methods for modulating hemoglobingene family expression
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
SG11201407486PA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating utrn expression
|
AU2013262649A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
AU2013262699A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating ATP2A2 expression
|
EP2854813B1
(de)
|
2012-05-31 |
2018-07-25 |
Bio-lab Ltd. |
Pyrazolotriazolylnukleosidanaloga und oligonukleotide damit
|
AU2013205064B2
(en)
|
2012-06-04 |
2015-07-30 |
Gen-Probe Incorporated |
Compositions and Methods for Amplifying and Characterizing HCV Nucleic Acid
|
DK2885638T3
(da)
|
2012-07-09 |
2020-07-20 |
Sienna Cancer Diagnostics Inc |
Molekylenet
|
PL2872485T3
(pl)
|
2012-07-13 |
2021-05-31 |
Wave Life Sciences Ltd. |
Asymetryczna grupa pomocnicza
|
AU2013287630B2
(en)
|
2012-07-13 |
2017-05-25 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant
|
AU2013205087B2
(en)
|
2012-07-13 |
2016-03-03 |
Gen-Probe Incorporated |
Method for detecting a minority genotype
|
WO2014012081A2
(en)
|
2012-07-13 |
2014-01-16 |
Ontorii, Inc. |
Chiral control
|
AU2013202793B2
(en)
|
2012-07-31 |
2014-09-18 |
Gen-Probe Incorporated |
System, method and apparatus for automated incubation
|
EP3640348A1
(de)
|
2012-08-30 |
2020-04-22 |
Gen-Probe Incorporated |
Mehrphasige nukleinsäureamplifikation
|
DK2895607T3
(da)
|
2012-09-12 |
2021-05-25 |
Quark Pharmaceuticals Inc |
Dobbeltstrengede oligonukleotidmolekyler til ddit4 og fremgangsmåder til anvendelse deraf
|
WO2014043291A1
(en)
|
2012-09-12 |
2014-03-20 |
Quark Pharmaceuticals, Inc. |
Double-stranded nucleic acid compounds
|
ES2704855T3
(es)
|
2012-09-12 |
2019-03-20 |
Quark Pharmaceuticals Inc |
Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas
|
WO2014043544A1
(en)
|
2012-09-14 |
2014-03-20 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
AU2013205122B2
(en)
|
2012-10-11 |
2016-11-10 |
Gen-Probe Incorporated |
Compositions and Methods for Detecting Human Papillomavirus Nucleic Acid
|
WO2014062691A2
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Compositions for modulating c9orf72 expression
|
WO2014062736A1
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Methods for monitoring c9orf72 expression
|
EP2914621B1
(de)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Neuartige ntrk1-fusionsmoleküle und verwendungen davon
|
AU2013205090B2
(en)
|
2012-12-07 |
2016-07-28 |
Gen-Probe Incorporated |
Compositions and Methods for Detecting Gastrointestinal Pathogen Nucleic Acid
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014130945A1
(en)
|
2013-02-25 |
2014-08-28 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
AU2014244116B9
(en)
|
2013-03-14 |
2020-08-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component C5 iRNA compositions and methods of use thereof
|
WO2014140167A1
(en)
|
2013-03-14 |
2014-09-18 |
Dsm Ip Assets B.V. |
Cell wall deconstruction enzymes of malbranchea cinnamomea and uses thereof
|
CA2905144C
(en)
|
2013-03-14 |
2023-08-22 |
Lyle J. Arnold |
Methods for amplification of nucleic acids on solid support
|
WO2014140165A1
(en)
|
2013-03-14 |
2014-09-18 |
Dsm Ip Assets B.V. |
Cell wall deconstruction enzymes of paecilomyces byssochlamydoides and uses thereof
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
US20160123959A1
(en)
|
2013-03-15 |
2016-05-05 |
Chromocell Corporation |
Methods and materials using signaling probes
|
EP2971033B8
(de)
|
2013-03-15 |
2019-07-10 |
ModernaTX, Inc. |
Herstellungsverfahren zur herstellung von rna-transkripten
|
EP2971165A4
(de)
|
2013-03-15 |
2016-11-23 |
Moderna Therapeutics Inc |
Entfernung von dna-fragmenten in mrna-herstellungsverfahren
|
CA2904863C
(en)
|
2013-03-15 |
2022-12-13 |
Lyle J. Arnold |
Methods for amplifying fragmented target nucleic acids utilizing an assembler sequence
|
EP2971124B1
(de)
|
2013-03-15 |
2019-12-25 |
Aegea Biotechnologies, Inc. |
Verfahren zur amplifikation von nukleinsäuren mit klemmungs-oligonukleotiden
|
EP2970971B1
(de)
|
2013-03-15 |
2020-09-02 |
Kambiz Shekdar |
Gemonänderung mit effektoroligonukleotiden für eine therapeutische behandlung
|
WO2014165825A2
(en)
|
2013-04-04 |
2014-10-09 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
JP6387084B2
(ja)
|
2013-05-01 |
2018-09-05 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
アポリポタンパク質c−iiiの発現を調節するための組成物および方法
|
AP2015008862A0
(en)
|
2013-05-22 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
TWI664187B
(zh)
|
2013-05-22 |
2019-07-01 |
阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
WO2014197835A2
(en)
|
2013-06-06 |
2014-12-11 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
CA2917348A1
(en)
|
2013-07-11 |
2015-01-15 |
Moderna Therapeutics, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
WO2015015496A1
(en)
|
2013-07-31 |
2015-02-05 |
Qbi Enterprises Ltd. |
Sphingolipid-polyalkylamine-oligonucleotide compounds
|
US20160208247A1
(en)
|
2013-07-31 |
2016-07-21 |
Qbi Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
EP4299767A3
(de)
|
2013-08-14 |
2024-03-27 |
Gen-Probe Incorporated |
Zusammensetzungen und verfahren zur detektion von hev-nukleinsäure
|
US9670492B2
(en)
*
|
2013-08-28 |
2017-06-06 |
Ionis Pharmaceuticals, Inc. |
Modulation of prekallikrein (PKK) expression
|
CA2923029A1
(en)
*
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
EP2853595A1
(de)
|
2013-09-30 |
2015-04-01 |
Soluventis GmbH |
NOTCH 1-spezifische siRNA-Moleküle
|
EP3052511A4
(de)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynukleotidmoleküle und verwendungen davon
|
TW202003849A
(zh)
|
2013-10-02 |
2020-01-16 |
美商艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
WO2015051283A1
(en)
|
2013-10-04 |
2015-04-09 |
Rana Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
MY197646A
(en)
|
2013-10-04 |
2023-06-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the alas1 gene
|
WO2015054676A2
(en)
|
2013-10-11 |
2015-04-16 |
Isis Pharmaceuticals, Inc. |
Compositions for modulating c9orf72 expression
|
EP3060680B1
(de)
|
2013-10-21 |
2019-02-27 |
The General Hospital Corporation |
Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und krebsbehandlung
|
AU2014362262B2
(en)
|
2013-12-12 |
2021-05-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component iRNA compositions and methods of use thereof
|
EP3865144A1
(de)
|
2013-12-20 |
2021-08-18 |
The General Hospital Corporation |
Verfahren und tests im zusammenhang mit zirkulierenden tumorzellen
|
EP3095460A4
(de)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
US10160969B2
(en)
|
2014-01-16 |
2018-12-25 |
Wave Life Sciences Ltd. |
Chiral design
|
KR102592370B1
(ko)
|
2014-02-11 |
2023-10-25 |
알닐람 파마슈티칼스 인코포레이티드 |
케토헥소키나제(KHK) iRNA 조성물 및 그의 사용 방법
|
PL3137596T3
(pl)
*
|
2014-05-01 |
2019-11-29 |
Ionis Pharmaceuticals Inc |
Kompozycja i sposoby modulowania ekspresji czynnika b dopełniacza
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
KR102410687B1
(ko)
|
2014-05-22 |
2022-06-22 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) irna 조성물 및 이의 사용 방법
|
CA2950589A1
(en)
|
2014-06-02 |
2015-12-10 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
AU2015289656A1
(en)
|
2014-07-16 |
2017-02-16 |
Modernatx, Inc. |
Circular polynucleotides
|
EP3185910A4
(de)
|
2014-08-29 |
2018-01-10 |
Children's Medical Center Corporation |
Verfahren und zusammensetzungen zur krebsbehandlung
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3209799B1
(de)
|
2014-10-20 |
2020-07-08 |
Gen-Probe Incorporated |
Lyselösung roter blutkörperchen
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
EP3904519A1
(de)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
WO2016083624A1
(en)
|
2014-11-28 |
2016-06-02 |
Silence Therapeutics Gmbh |
Means for inhibiting the expression of edn1
|
SG11201704660YA
(en)
|
2014-12-08 |
2017-07-28 |
Berg Llc |
Use of markers including filamin a in the diagnosis and treatment of prostate cancer
|
JP6944873B2
(ja)
|
2015-01-09 |
2021-10-06 |
ジェン−プローブ・インコーポレーテッド |
細菌性膣症を診断するための方法および組成物
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
WO2016130943A1
(en)
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
WO2016149357A1
(en)
|
2015-03-16 |
2016-09-22 |
Gen-Probe Incorporated |
Methods and compositions for detecting bacterial nucleic acid and diagnosing bacterial vaginosis
|
EP3271460A4
(de)
|
2015-03-17 |
2019-03-13 |
The General Hospital Corporation |
Rna-interaktom des polycomb-repressiven komplexes 1 (prc1)
|
WO2016160721A1
(en)
|
2015-03-27 |
2016-10-06 |
President And Fellows Of Harvard College |
Modified t cells and methods of making and using the same
|
MX2017012610A
(es)
|
2015-04-08 |
2018-03-16 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
CN113265404A
(zh)
|
2015-04-16 |
2021-08-17 |
Ionis制药公司 |
用于调节c9orf72表达的组合物
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
EA201890619A1
(ru)
|
2015-09-02 |
2018-09-28 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ iRNA ЛИГАНДА 1 БЕЛКА ЗАПРОГРАММИРОВАННОЙ ГИБЕЛИ КЛЕТОК 1 (PD-L1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
US11434486B2
(en)
|
2015-09-17 |
2022-09-06 |
Modernatx, Inc. |
Polynucleotides containing a morpholino linker
|
WO2017079291A1
(en)
|
2015-11-02 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating c90rf72
|
EP4249609A3
(de)
|
2016-01-04 |
2023-12-20 |
Gen-Probe Incorporated |
Verfahren und zusammensetzungen zum nachweis von candida-spezies
|
EP3228326A1
(de)
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleinsäure verbunden mit einem dreiwertigen glykokonjugat
|
US11365415B2
(en)
|
2016-04-14 |
2022-06-21 |
University Of Florida Research Foundation, Inc. |
Use of miR-223-3p as a cancer therapeutic and method for treating cancer using the same
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
EP3449002A4
(de)
|
2016-04-29 |
2019-09-25 |
Nanyang Technological University |
G-quadruplex-haltige antisense-oligonukleotide
|
EP3469083A1
(de)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
|
AU2017346854B2
(en)
|
2016-10-19 |
2024-05-23 |
Gen-Probe Incorporated |
Compositions and methods for detecting or quantifying hepatitis C virus
|
CA3042451A1
(en)
|
2016-11-21 |
2018-05-24 |
Gen-Probe Incorporated |
Compositions and methods for detecting or quantifying hepatitis b virus
|
AU2017376950B2
(en)
|
2016-12-16 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
|
BR112019012825A2
(pt)
|
2016-12-22 |
2019-11-26 |
Intellia Therapeutics Inc |
composições e métodos para tratar deficiência de alfa-1 antitripsina
|
CA3057154A1
(en)
|
2017-03-24 |
2018-09-27 |
Gen-Probe Incorporated |
Compositions and methods for detecting or quantifying parainfluenza virus
|
EP3601619A1
(de)
|
2017-03-24 |
2020-02-05 |
Gen-Probe Incorporated |
Zusammensetzungen und verfahren zum nachweis viraler pathogene in proben
|
WO2018183124A1
(en)
|
2017-03-25 |
2018-10-04 |
Gen-Probe Incorporated |
Compositions, methods and kits to detect adenovirus, metapneumovirus and/or rhinovirus nucleic acids
|
WO2018185253A1
(en)
|
2017-04-05 |
2018-10-11 |
Silence Therapeutics Gmbh |
Ligand modified double-stranded nucleic acids
|
EP3385272A1
(de)
|
2017-04-05 |
2018-10-10 |
Silence Therapeutics GmbH |
Weitere neuartige oligonukleotid-ligand-konjugate
|
WO2018185252A1
(en)
|
2017-04-05 |
2018-10-11 |
Silence Therapeutics Gmbh |
Nucleic acid conjugates
|
MA50278A
(fr)
|
2017-04-18 |
2020-02-26 |
Alnylam Pharmaceuticals Inc |
Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
|
WO2018209068A1
(en)
|
2017-05-11 |
2018-11-15 |
Gen-Probe Incorporated |
Compositions and methods for isolating target nucleic acids
|
AU2018281196B2
(en)
|
2017-06-07 |
2022-04-28 |
Gen-Probe Incorporated |
Detecting Babesia species nucleic acid in a sample
|
CA3156539A1
(en)
|
2017-07-10 |
2019-01-17 |
Gen-Probe Incorporated |
Analytical systems and methods for nucleic acid amplification using sample assigning parameters
|
JP7277432B2
(ja)
|
2017-07-13 |
2023-05-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
乳酸脱水素酵素A(LDHA)iRNA組成物及びその使用方法
|
CA3072452A1
(en)
|
2017-08-11 |
2019-02-14 |
Gen-Probe Incorporated |
Compositions and methods for detecting staphylococcus aureus
|
BR112020005287A2
(pt)
|
2017-09-29 |
2020-09-24 |
Intellia Therapeutics, Inc. |
composições e métodos para edição de gene ttr e tratar amiloidose attr
|
AU2018339089A1
(en)
|
2017-09-29 |
2020-04-09 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
EP3704252A1
(de)
|
2017-11-01 |
2020-09-09 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
EP3710587A1
(de)
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein-c3 kisspeptin 1 (kiss1)-irna-zusammensetzungen und verfahren zur verwendung davon
|
CN111465707A
(zh)
|
2017-11-17 |
2020-07-28 |
简·探针公司 |
用于检测C1orf43核酸的组合物和方法
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
US11662281B2
(en)
|
2017-12-13 |
2023-05-30 |
Gen-Probe Incorporated |
Compositions and methods for biological sample processing
|
EP3724354A1
(de)
|
2017-12-15 |
2020-10-21 |
Gen-Probe Incorporated |
Zusammensetzungen und verfahren zum nachweis von toxigenem clostridium difficile
|
CA3086343A1
(en)
|
2017-12-18 |
2019-06-27 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
EP3746225A1
(de)
|
2018-01-29 |
2020-12-09 |
Gen-Probe Incorporated |
Analytische systeme und verfahren
|
CN112166118A
(zh)
|
2018-03-22 |
2021-01-01 |
德克萨斯大学体系董事会 |
治疗自身免疫性疾病和癌症的可溶性白介素-7受体(sIL7R)调节疗法
|
EP3549610A1
(de)
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Nukleinsäurekonjugate
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
GB2597566B
(en)
|
2018-06-13 |
2023-02-01 |
Gen Probe Inc |
Compositions and methods for detecting group B streptococcus nucleic acid
|
US20210317515A1
(en)
|
2018-07-10 |
2021-10-14 |
Gen-Probe Incorporated |
Methods and systems for detecting and quantifying nucleic acids
|
CN112867795A
(zh)
|
2018-07-31 |
2021-05-28 |
因特利亚治疗公司 |
用于执行羟基酸氧化酶1(hao1)基因编辑以治疗1型原发性高草酸尿症(ph1)的组合物和方法
|
US20210332449A1
(en)
|
2018-08-01 |
2021-10-28 |
Gen-Probe Incorporated |
Compositions and methods for detecting nucleic acids of epstein-barr virus
|
WO2020033557A1
(en)
|
2018-08-08 |
2020-02-13 |
Gen-Probe Incorporated |
Compositions, methods and kits for detecting mycoplasma genitalium
|
WO2020036862A1
(en)
|
2018-08-13 |
2020-02-20 |
Alnylam Pharmaceuticals, Inc. |
HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
US11987792B2
(en)
|
2018-08-16 |
2024-05-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
US20220074002A1
(en)
|
2018-08-21 |
2022-03-10 |
Gen-Probe Incorporated |
Compositions and methods for amplifying, detecting or quantifying human cytomegalovirus
|
EP3841222A1
(de)
|
2018-08-24 |
2021-06-30 |
Gen-Probe Incorporated |
Verfahren und zusammensetzungen zum nachweis von bakterieller nukleinsäure und zur diagnose von bakterieller vaginose
|
EP3853364A1
(de)
|
2018-09-18 |
2021-07-28 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
|
AU2019350777A1
(en)
|
2018-09-27 |
2021-05-20 |
Gen-Probe Incorporated |
Compositions and methods for detecting Bordetella pertussis and Bordetellaparapertussis nucleic acid
|
MX2021003457A
(es)
|
2018-09-28 |
2021-07-16 |
Intellia Therapeutics Inc |
Composiciones y métodos para la edición génica de lactato deshidrogenasa (ldha).
|
CN113227374A
(zh)
|
2018-10-16 |
2021-08-06 |
因特利亚治疗公司 |
用于免疫疗法的组合物和方法
|
KR20210102882A
(ko)
|
2018-10-18 |
2021-08-20 |
인텔리아 테라퓨틱스, 인크. |
핵산 구조체 및 사용 방법
|
JP2022505381A
(ja)
|
2018-10-18 |
2022-01-14 |
インテリア セラピューティクス,インコーポレーテッド |
アルファ1アンチトリプシン欠乏症を治療するための組成物及び方法
|
CN113260701A
(zh)
|
2018-10-18 |
2021-08-13 |
英特利亚治疗股份有限公司 |
用于表达因子ix的组合物和方法
|
KR20210102883A
(ko)
|
2018-10-18 |
2021-08-20 |
인텔리아 테라퓨틱스, 인크. |
알부민 좌위로부터 트랜스진을 발현하기 위한 조성물 및 방법
|
AU2019365821A1
(en)
|
2018-10-22 |
2021-06-10 |
Gen-Probe Incorporated |
Compositions and methods for amplifying, detecting or quantifying human polyomavirus BK virus
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
CN113631709A
(zh)
|
2018-12-20 |
2021-11-09 |
普拉克西斯精密药物股份有限公司 |
用于治疗kcnt1相关病症的组合物和方法
|
TW202030333A
(zh)
|
2018-12-20 |
2020-08-16 |
美商簡 探針公司 |
用於檢測瘧原蟲物種核酸之組成物及方法
|
SI3897672T1
(sl)
|
2018-12-20 |
2024-02-29 |
Humabs Biomed Sa |
Kombinirana terapija HBV
|
AU2020209186A1
(en)
|
2019-01-16 |
2021-09-09 |
Genzyme Corporation |
Serpinc1 iRNA compositions and methods of use thereof
|
WO2020197987A1
(en)
|
2019-03-22 |
2020-10-01 |
Gen-Probe Incorporated |
Compositions and methods for detecting group a streptococcus
|
MA55527A
(fr)
|
2019-03-28 |
2022-02-09 |
Intellia Therapeutics Inc |
Polynucléotides, compositions et procédés d'expression de polypeptides
|
EP3946598A1
(de)
|
2019-03-28 |
2022-02-09 |
Intellia Therapeutics, Inc. |
Zusammensetzungen und verfahren mit einer ttr-guide-rna und einem polynukleotid, das für ein rna-geführtes dna-bindungsmittel codiert
|
JP2022525429A
(ja)
|
2019-03-28 |
2022-05-13 |
インテリア セラピューティクス,インコーポレイテッド |
コルチコステロイドを含む、ttr遺伝子編集およびattrアミロイドーシスを治療するための組成物および方法、またはその使用
|
SG11202111824UA
(en)
|
2019-04-30 |
2021-11-29 |
Larimar Therapeutics Inc |
Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
|
CA3137749C
(en)
|
2019-05-03 |
2023-12-05 |
Gen-Probe Incorporated |
Receptacle transport system for an analytical system
|
WO2020232024A1
(en)
|
2019-05-13 |
2020-11-19 |
Vir Biotechnology, Inc. |
Compositions and methods for treating hepatitis b virus (hbv) infection
|
AU2020299621A1
(en)
|
2019-07-03 |
2022-02-24 |
Gen-Probe Incorporated |
Oligonucleotides for use in determining the presence of Trichomonas vaginalis in a sample.
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4007811A2
(de)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4018004A1
(de)
|
2019-08-23 |
2022-06-29 |
Gen-Probe Incorporated |
Zusammensetzungen, verfahren und kits zum nachweis von treponema pallidum
|
BR112022003505A2
(pt)
|
2019-08-27 |
2022-05-24 |
Vertex Pharma |
Composições e métodos para tratamento de distúrbios associados a dna repetitivo
|
BR112022003860A2
(pt)
|
2019-09-03 |
2022-08-16 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para inibir a expressão do gene lect2
|
WO2021046270A1
(en)
|
2019-09-05 |
2021-03-11 |
Gen-Probe Incorporated |
Detection of chlamydia trachomatis nucleic acid variants
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
CN115176004A
(zh)
|
2019-10-22 |
2022-10-11 |
阿尔尼拉姆医药品有限公司 |
补体成分C3 iRNA组合物及其使用方法
|
AR120341A1
(es)
|
2019-11-01 |
2022-02-09 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
PE20230179A1
(es)
|
2019-11-13 |
2023-02-01 |
Alnylam Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt)
|
US20220396786A1
(en)
|
2019-11-14 |
2022-12-15 |
Gen-Probe Incorporated |
Compositions and Methods for Capturing Target Nucleic Acids
|
EP4061945A1
(de)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
|
EP4073251A1
(de)
|
2019-12-13 |
2022-10-19 |
Alnylam Pharmaceuticals, Inc. |
Irna-wirkstoffzusammensetzungen des open reading frame 72 (c9orf72) des menschlichen chromosoms 9 und verfahren zu ihrer verwendung
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
EP4090768B1
(de)
|
2020-01-16 |
2024-03-13 |
DNAe Diagnostics Limited |
Zusammensetzungen, kits und verfahren zur isolierung von zielpolynukleotiden
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
JP2023512075A
(ja)
|
2020-01-31 |
2023-03-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
オリゴヌクレオチドを特徴解析するための液体クロマトグラフィーおよび質量分析の使用
|
JP2023514190A
(ja)
|
2020-02-10 |
2023-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Vegf-a発現をサイレンシングするための組成物および方法
|
CN115397989A
(zh)
|
2020-02-18 |
2022-11-25 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白C3(APOC3)iRNA组合物及其使用方法
|
WO2021174031A2
(en)
*
|
2020-02-28 |
2021-09-02 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating splicing of pre-mrna
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
CN115485383A
(zh)
|
2020-03-06 |
2022-12-16 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
EP4121534A1
(de)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
|
CN116209759A
(zh)
|
2020-03-26 |
2023-06-02 |
阿尔尼拉姆医药品有限公司 |
冠状病毒iRNA组合物及其使用方法
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
CN117377763A
(zh)
|
2020-04-06 |
2024-01-09 |
阿尔尼拉姆医药品有限公司 |
用于沉默myoc表达的组合物和方法
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
EP4133076A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
|
JP2023523993A
(ja)
|
2020-04-27 |
2023-06-08 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アポリポタンパク質E(ApoE)iRNA剤組成物およびその使用方法
|
CA3181340A1
(en)
|
2020-04-28 |
2021-11-04 |
Intellia Therapeutics, Inc. |
Methods of in vitro cell delivery
|
BR112022021136A2
(pt)
|
2020-04-30 |
2022-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
|
EP4146821A1
(de)
|
2020-05-07 |
2023-03-15 |
Grifols Diagnostic Solutions Inc. |
Verfahren und zusammensetzungen zum nachweis von sars-cov-2-nukleinsäure
|
EP4150086A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
EP4150088A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von argininosuccinat-synthetase (ass1)
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
CN115885042A
(zh)
|
2020-05-22 |
2023-03-31 |
波涛生命科学有限公司 |
双链寡核苷酸组合物及其相关方法
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
EP3922720A1
(de)
|
2020-06-09 |
2021-12-15 |
Universidad de Murcia |
Therapie zur verhinderung unerwünschter kardialer remodellierung nach einem akuten myokardinfarkt
|
IL299063A
(en)
|
2020-06-18 |
2023-02-01 |
Alnylam Pharmaceuticals Inc |
Xanthine dehydrogenase (xdh) RNA compositions and methods of using them
|
MX2022015765A
(es)
|
2020-06-24 |
2023-03-27 |
Vir Biotechnology Inc |
Anticuerpos modificados neutralizadores del virus de la hepatitis b y sus usos.
|
AU2021308095A1
(en)
|
2020-07-17 |
2023-03-09 |
Gen-Probe Incorporated |
Detection of macrolide-resistant mycoplasma genitalium
|
WO2022047359A1
(en)
|
2020-08-31 |
2022-03-03 |
Berg Llc |
Protein biomarkers for pancreatic cancer
|
US20220096606A1
(en)
|
2020-09-09 |
2022-03-31 |
Vertex Pharmaceuticals Incorporated |
Compositions and Methods for Treatment of Duchenne Muscular Dystrophy
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法
|
EP4232379A2
(de)
|
2020-10-21 |
2023-08-30 |
Gen-Probe Incorporated |
Flüssigkeitsbehälterverwaltungssystem
|
EP4232581A1
(de)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von primärer hyperoxalurie
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022098933A1
(en)
|
2020-11-06 |
2022-05-12 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of dm1 with slucas9 and sacas9
|
TW202237841A
(zh)
|
2020-11-13 |
2022-10-01 |
美商艾拉倫製藥股份有限公司 |
凝血因子V(F5)iRNA組成物及其使用方法
|
CA3201452A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
EP4259795A1
(de)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2023552816A
(ja)
|
2020-12-11 |
2023-12-19 |
インテリア セラピューティクス,インコーポレイテッド |
細胞内のmhcクラスiiを低減する組成物及び方法
|
AU2021394998A1
(en)
|
2020-12-11 |
2023-06-29 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing involving deamination
|
US20240175020A1
(en)
|
2020-12-23 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
KR20230124664A
(ko)
|
2020-12-23 |
2023-08-25 |
인텔리아 테라퓨틱스, 인크. |
세포에서 hla-a를 감소시키기 위한 조성물 및 방법
|
AU2021410751A1
(en)
|
2020-12-23 |
2023-07-13 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying ciita in a cell
|
TW202235615A
(zh)
|
2020-12-30 |
2022-09-16 |
美商英特利亞醫療公司 |
工程化之t細胞
|
EP4274896A1
(de)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4277658A1
(de)
|
2021-01-15 |
2023-11-22 |
Board of Regents, The University of Texas System |
Trans-komplementierungssystem für sars-cov-2
|
JP2024505678A
(ja)
|
2021-02-08 |
2024-02-07 |
インテリア セラピューティクス,インコーポレイテッド |
免疫療法のためのリンパ球活性化遺伝子3(lag3)組成物及び方法
|
EP4288525A1
(de)
|
2021-02-08 |
2023-12-13 |
Intellia Therapeutics, Inc. |
Natürliche killerzellenrezeptor 2b4-zusammensetzungen und verfahren zur immuntherapie
|
JP2024506016A
(ja)
|
2021-02-08 |
2024-02-08 |
インテリア セラピューティクス,インコーポレイテッド |
免疫療法のためのt細胞免疫グロブリン及びムチンドメイン3(tim3)組成物及び方法
|
AU2022220704A1
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
EP4298220A1
(de)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4298221A1
(de)
|
2021-02-26 |
2024-01-03 |
Vertex Pharmaceuticals Incorporated |
Zusammensetzungen und verfahren zur behandlung von myotoner dystrophie typ 1 mit crispr/slucas9
|
BR112023016645A2
(pt)
|
2021-02-26 |
2023-11-14 |
Alnylam Pharmaceuticals Inc |
Composições de irna de ceto-hexoquinase (khk) e métodos de uso das mesmas
|
TW202302848A
(zh)
|
2021-02-26 |
2023-01-16 |
美商維泰克斯製藥公司 |
以crispr/sacas9治療第1型肌強直性營養不良之組合物及方法
|
MX2023010249A
(es)
|
2021-03-04 |
2023-09-15 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni de proteina similar a la angiopoyetina 3 (angptl3) y metodos para usarlas.
|
EP4305169A1
(de)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022197634A1
(en)
|
2021-03-15 |
2022-09-22 |
Gen-Probe Incorporated |
Compositions and methods for biological sample processing
|
US20240165271A1
(en)
|
2021-03-26 |
2024-05-23 |
The Board Of Regents Of The University Of Texas System |
Nucleotide editing to reframe dmd transcripts by base editing and prime editing
|
TW202305134A
(zh)
|
2021-03-29 |
2023-02-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓蛋白(HTT)iRNA劑組成物及其使用方法
|
EP4314293A1
(de)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022216841A1
(en)
|
2021-04-06 |
2022-10-13 |
Berg Llc |
Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
|
EP4320443A1
(de)
|
2021-04-06 |
2024-02-14 |
BPGbio, Inc. |
Proteinmarker zur prognose der brustkrebsprogression
|
WO2022216846A1
(en)
|
2021-04-06 |
2022-10-13 |
Berg Llc |
Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
|
AU2022264478A1
(en)
|
2021-04-26 |
2023-10-12 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
JP2024519293A
(ja)
|
2021-04-29 |
2024-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
シグナル伝達兼転写活性化因子6(STAT6)iRNA組成物およびその使用方法
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
EP4341405A1
(de)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
TW202317762A
(zh)
|
2021-06-02 |
2023-05-01 |
美商艾拉倫製藥股份有限公司 |
含有類PATATIN磷脂酶結構域3(PNPLA3)的iRNA組成物及其使用方法
|
IL308743A
(en)
|
2021-06-04 |
2024-01-01 |
Alnylam Pharmaceuticals Inc |
Compositions of human chromosome 9 open reading frame 72 iRNA factor (C9ORF72) and methods of using them
|
WO2022260939A2
(en)
|
2021-06-08 |
2022-12-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
CA3224995A1
(en)
|
2021-06-22 |
2022-12-29 |
Intellia Therapeutics, Inc. |
Methods for in vivo editing of a liver gene
|
EP4363574A1
(de)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278576A1
(en)
|
2021-06-30 |
2023-01-05 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
GB202110479D0
(en)
|
2021-07-21 |
2021-09-01 |
Dnae Diagnostics Ltd |
Compositions, kits and methods for sequencing target polynucleotides
|
WO2023002203A1
(en)
|
2021-07-21 |
2023-01-26 |
Dnae Diagnostics Limited |
Method and system comprising a cartridge for sequencing target polynucleotides
|
GB202110485D0
(en)
|
2021-07-21 |
2021-09-01 |
Dnae Diagnostics Ltd |
Compositions, kits and methods for sequencing target polynucleotides
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
EP4377481A1
(de)
|
2021-07-27 |
2024-06-05 |
Gen-Probe Incorporated |
Zusammensetzungen und verfahren zum nachweis von gastrointestinalen pathogenen
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
WO2023014677A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
AU2022324003A1
(en)
|
2021-08-04 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
IL310407A
(en)
|
2021-08-13 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Factor XII (F12) IRNA compositions and methods of using them
|
CN117940153A
(zh)
|
2021-08-24 |
2024-04-26 |
因特利亚治疗公司 |
用于基于细胞的疗法的程序性细胞死亡蛋白1(pd1)组合物和方法
|
WO2023039444A2
(en)
|
2021-09-08 |
2023-03-16 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
US20230193406A1
(en)
|
2021-09-22 |
2023-06-22 |
Herbalife International Of America, Inc. |
Methods and compositions for processing botanical materials
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
WO2023076451A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
WO2023081200A2
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
TW202325848A
(zh)
|
2021-11-03 |
2023-07-01 |
美商英特利亞醫療公司 |
用於基因體編輯之多核苷酸、組合物及方法
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023172926A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
WO2023172927A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 44, 50, and 53 for treatment of duchenne muscular dystrophy
|
WO2023185697A2
(en)
|
2022-03-29 |
2023-10-05 |
Accuredit Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treatment of transthyretin amyloidosis
|
WO2023196937A1
(en)
|
2022-04-06 |
2023-10-12 |
Larimar Therapeutics, Inc. |
Frataxin-sensitive markers for monitoring frataxin replacement therapy
|
WO2023205606A1
(en)
|
2022-04-18 |
2023-10-26 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for enhancing aav therapy and decreasing tropism of aav to the liver
|
WO2023205148A1
(en)
|
2022-04-19 |
2023-10-26 |
Intellia Therapeutics, Inc. |
Chimeric antigen receptor compositions and uses
|
WO2023240201A1
(en)
|
2022-06-08 |
2023-12-14 |
Larimar Therapeutics, Inc. |
Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
|
WO2023245109A2
(en)
|
2022-06-16 |
2023-12-21 |
Intellia Therapeutics, Inc. |
Compositions and methods for genomic editing
|
WO2023245108A2
(en)
|
2022-06-16 |
2023-12-21 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing mhc class i in a cell
|
WO2023245113A1
(en)
|
2022-06-16 |
2023-12-21 |
Intellia Therapeutics, Inc. |
Methods and compositions for genetically modifying a cell
|
WO2024006955A1
(en)
|
2022-06-29 |
2024-01-04 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
WO2024020352A1
(en)
|
2022-07-18 |
2024-01-25 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024054924A1
(en)
|
2022-09-08 |
2024-03-14 |
Gen-Probe Incorporated |
Method of detecting nucleic acid analytes using dual-specificity primers
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024061296A2
(en)
|
2022-09-22 |
2024-03-28 |
Accuredit Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024102677A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|